RT Journal Article
SR Electronic
T1 The AP-1 complex regulates AXL expression and determines sensitivity to PI3Kα inhibition in esophagus and head and neck squamous cell carcinoma
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 415752
DO 10.1101/415752
A1 Mai Bdarny
A1 Manu Prasad
A1 Noa Balaban
A1 Joshua Ben-Zion
A1 Anat Bahat Dinur
A1 Reidar Grénman
A1 Limor Cohen
A1 Moshe Elkabets
YR 2018
UL http://biorxiv.org/content/early/2018/09/13/415752.abstract
AB AXL overexpression is a common resistance mechanism to anti-cancer therapies, including the p110α isoform specific inhibitor of the phosphoinositide 3-kinase (PI3K), BYL719, in esophagus and head and neck squamous cell carcinoma (ESCC, HNSCC respectively). However, the mechanisms underlying AXL overexpression in resistance to BYL719 remained elusive. Here we demonstrated that the AP-1 transcription factors, c-JUN and c-FOS, regulates AXL overexpression in HNSCC and ESCC. AXL and c-JUN expression is correlated in HNSCC patients, and in HNSCC and ESCC cell lines. Silencing of c-JUN and c-FOS expression in tumor cells reduced AXL expression, and enhanced sensitivity of human papilloma virus positive (HPVPos) and negative (HPVNeg) tumor cells to BYL719 in vitro. Blocking of the c-JUN N-terminal kinase (JNK), using SP600125, in combination with BYL719 resulted in down-regulation of AXL expression, and potently inhibited mTOR pathway. Synergistic anti-proliferative effect was detected between BYL719 and SP600125 in 15 tumor cell lines in vitro. In-vivo, this drug combination induced tumor growth arrest in cell line and patients-derived xenograft models, and in syngeneic head and neck cancer models. Collectively, our data suggests that JNK inhibition in combination with anti-PI3K therapy is a new therapeutic strategy that may be tested in HPVPos and HPVNeg HNSCC and ESCC patients.